Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety

Journal of Neuroscience

Volumn 24, Issue 35, 2004, Pages 7762-7770

  Murgatroyd, Chris ^a   Wigger, Alexandra ^a   Frank, Elisabeth ^a   Singewald, Nicolas ^b   Bunck, Mirjam ^a   Holsboer, Florian ^a   Landgraf, Rainer ^a   Spengler, Dietmar ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anxiety; Arginine vasopressin; CBF A; Common variant common disease hypothesis; Depression; Hypothalamic pituitary adrenal axis

Indexed keywords

CARG BOX BINDING FACTOR A; COMPLEMENTARY DNA; DNA BINDING PROTEIN; DOUBLE STRANDED DNA; MESSENGER RNA; RNA; SINGLE STRANDED DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SRF; UNCLASSIFIED DRUG; VASOPRESSIN;

ALLELE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; BINDING SITE; CARG BOX; CARG ELEMENT; DEPRESSION; DNA BINDING; DNA STRUCTURE; GENE REPRESSION; GENETIC TRANSCRIPTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOHISTOCHEMISTRY; INBRED STRAIN; MAJOR DEPRESSION; MENTAL DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASOPRESSIN RELEASE;

ALLELES; ANIMALS; ANXIETY; ARGININE VASOPRESSIN; BONE NEOPLASMS; CELL LINE, TUMOR; DNA, SINGLE-STRANDED; DNA-BINDING PROTEINS; EXPLORATORY BEHAVIOR; FEAR; GENE EXPRESSION REGULATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INBREEDING; MAZE LEARNING; OSTEOSARCOMA; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RATS; RATS, WISTAR; REACTION TIME; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 4444325412     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1614-04.2004     Document Type: Article

References (34)

1. Bemark M, Olsson H, Heinegard D, Leanderson T (1998) Purification and characterization of a protein binding to the SP6 kappa promoter. A potential role for CArG-box binding factor-A in kappa transcription. J Biol Chem 273:18881-18890.
2. Blume A, Seifert K, Lebrun CJ, Mollenhoff E, Gass P, Unger T, Herdegen T (1998) Differential time course of angiotensin-induced AP-1 and Krox proteins in the rat lamina terminalis and hypothalamus. Neurosci Lett 241:87-90.
3. Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB, Montminy M (2003) TORCs: transducers of regulated CREB activity. Mol Cell 12:413-423.
4. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431.
5. Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP (1999) E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochem J 344:961-970.
6. Falconer DS, Mackay TFC (1996) Introduction to quantitative genetics. Essex, UK: Longman.
7. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370-6375.
8. Herdegen T, Blume A, Buschmann T, Georgakopoulos E, Winter C, Schmid W, Hsieh TF, Zimmermann M, Gass P (1997) Expression of activating transcription factor-2, serum response factor and cAMP/Ca response element binding protein in the adult rat brain following generalized seizures, nerve fibre lesion and ultraviolet irradiation. Neuroscience 81:199-212.
9. Hoffmann A, Ciani E, Boeckardt J, Holsboer F, Journot L, Spengler D (2003) Transcriptional activities of the zinc finger protein Zac are differentially controlled by DNA binding. Mol Cell Biol 23:988-1003.
10. Hyde-DeRuyscher RP, Jennings E, Shenk T (1995) DNA binding sites for the transcriptional activator/repressor YYl. Nucleic Acids Res 23:4457-4465.
11. Iwasaki Y, Oiso Y, Saito H, Majzoub JA (1997) Positive and negative regulation of the rat vasopressin gene promoter. Endocrinology 138:5266-5274.
12. Kamada S, Miwa T (1992) A protein binding to CArG box motifs and to single-stranded DNA functions as a transcriptional repressor. Gene 119:229-236.
13. Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JM, Holsboer F, Landgraf R, Neumann ID (2002) Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26:94-105.
14. Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R (2003) Reduction in hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioural and neuroendocrine effects of chronic paroxetine treatment in a psychpathological rat model. Neuropsychopharmacology 28:235-243.
15. Kelm Jr RJ, Wang SX, Polikandriotis JA, Strauch AR (2003) Structure/function analysis of mouse Purbeta, a single-stranded DNA-binding repressor of vascular smooth muscle alpha-actin gene transcription. J Biol Chem 278:38749-38757.
16. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F, Engelmann M (1995) V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 15:4250-4258.
17. Liebsch G, Montkowski A, Holsboer F, Landgraf R (1998) Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res 94:301-310.
18. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33:177-182.
19. Martin KA, Gualberto A, Kolman MF, Lowry J, Walsh K (1997) A competitive mechanism of CArG element regulation by YY1 and SRF: implications for assessment of Phox1/MHox transcription factor interactions at CArG elements. DNA Cell Biol 16:653-661.
20. Mikheev AM, Mikheev SA, Zhang Y, Aebersold R, Zarbl H (2000) CArG binding factor A (CBF-A) is involved in transcriptional regulation of the rat Ha-ras promoter. Nucleic Acids Res 28:3762-3770.
21. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244.
22. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25.
23. Pitkow LJ, Sharer CA, Ren X, Insel TR, Terwilliger EF, Young LJ (2001) Facilitation of affiliation and pair-bond formation by vasopressin receptor gene transfer into the ventral forebrain of a monogamous vole. J Neurosci 21:7392-7396.
24. Rushlow WJ, Rajakumar N, Flumerfelt BA, Naus CC (1999) Characterization of CArG-binding protein A initially identifiedby differential display. Neuroscience 94:637-649.
25. Salchner P, Singewald N (2002) Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43:1238-1248.
26. Salome N, Salchner P, Viltart O, Sequeira H, Wigger A, Landgraf R, Singewald N (2004) Neurobiological correlates of high (HAB) versus low anxiety-related behavior (LAB): differential Fos expression in HAB and LAB rats. Biol Psychiatry 55:715-723.
27. Scott LV, Dinan TG (2002) Vasopressin as a target for antidepressant development: an assessment of the available evidence. J Affect Disord 72:113-124.
28. Scott SD, Joiner MC, Marples B (2002) Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 9:1396-1402.
29. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger Jr JI, Craddock N, DePaulo JR, Baron M, Gershon ES, Ekholm J, Cichon S, Turecki G, Claes S, Kelsoe JR, Schofield PR, Badenhop RF, Morissette J, Coon H, Blackwood D, et al. (2003) Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 73:49-62.
30. Stringer JL, Belaguli NS, Iyer D, Schwartz RJ, Balasubramanyam A (2002) Developmental expression of serum response factor in the rat central nervous system. Brain Res Dev Brain Res 138:81-86.
31. Treisman R (1987) Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J 6:2711-2717.
32. Treisman R (1990) The SRE: a growth factor responsive transcriptional regulator. Semin Cancer Biol 1:47-58.
33. Umar A, Luider TM, Berrevoets CA, Grootegoed JA, Brinkmann AO (2003) Proteomic analysis of androgen-regulated protein expression in a mouse fetal vas deferens cell line. Endocrinology 144:1147-1154.
34. Wigger A, Sanchez MM, Mathys KC, Ebner K, Frank E, Liu D, Kresse A, Neumann ID, Holsboer F, Plotsky PM, Landgraf R (2004) Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 29:1-14.